Literature DB >> 19336012

Curable metastatic colorectal cancer: recommended paradigms.

Richard N Berri1, Eddie K Abdalla.   

Abstract

"Cure" for patients with stage IV colorectal cancer remains elusive, but for a growing subset of patients with colorectal liver metastases (CLMs), cure (ie, > 10-year survival without evidence of disease) is achieved in at least 17% of resected patients. Candidates for resection include those with limited and in some cases extensive hepatic disease, and in highly selected cases, patients with extrahepatic disease. Number, size, and bilaterality of CLMs no longer stand as absolute contraindications to surgery. Chemotherapy has further advanced the field of surgery for CLMs, enabling an additional group of patients who present with unresectable disease to undergo surgery after downsizing with chemotherapy. Modern surgical techniques and liver preparation allow resection after chemotherapy, with excellent results. This article summarizes the current multidisciplinary approach to treatment of CLMs. The definition of resectability, conversion of unresectable CLMs to resectable ones, advances in surgical techniques, advances in chemotherapy, and predictors of outcome are detailed.

Entities:  

Mesh:

Year:  2009        PMID: 19336012     DOI: 10.1007/s11912-009-0029-z

Source DB:  PubMed          Journal:  Curr Oncol Rep        ISSN: 1523-3790            Impact factor:   5.075


  42 in total

1.  Standardized measurement of the future liver remnant prior to extended liver resection: methodology and clinical associations.

Authors:  J N Vauthey; A Chaoui; K A Do; M M Bilimoria; M J Fenstermacher; C Charnsangavej; M Hicks; G Alsfasser; G Lauwers; I F Hawkins; J Caridi
Journal:  Surgery       Date:  2000-05       Impact factor: 3.982

2.  Surgical wound healing complications in metastatic colorectal cancer patients treated with bevacizumab.

Authors:  Frank A Scappaticci; Louis Fehrenbacher; Thomas Cartwright; John D Hainsworth; William Heim; Jordan Berlin; Fairooz Kabbinavar; William Novotny; Somnath Sarkar; Herbert Hurwitz
Journal:  J Surg Oncol       Date:  2005-09-01       Impact factor: 3.454

3.  Selection of patients for resection of hepatic colorectal metastases: expert consensus statement.

Authors:  Chusilp Charnsangavej; Bryan Clary; Yuman Fong; Axel Grothey; Timothy M Pawlik; Michael A Choti
Journal:  Ann Surg Oncol       Date:  2006-09-01       Impact factor: 5.344

4.  Survival of patients evaluated by FDG-PET before hepatic resection for metastatic colorectal carcinoma: a prospective database study.

Authors:  S M Strasberg; F Dehdashti; B A Siegel; J A Drebin; D Linehan
Journal:  Ann Surg       Date:  2001-03       Impact factor: 12.969

5.  Complete response of colorectal liver metastases after chemotherapy: does it mean cure?

Authors:  Stéphane Benoist; Antoine Brouquet; Christophe Penna; Catherine Julié; Mostafa El Hajjam; Sophie Chagnon; Emmanuel Mitry; Philippe Rougier; Bernard Nordlinger
Journal:  J Clin Oncol       Date:  2006-08-20       Impact factor: 44.544

6.  Liver histology and surgical outcomes after preoperative chemotherapy with fluorouracil plus oxaliplatin in colorectal cancer liver metastases.

Authors:  Thomas Aloia; Mylène Sebagh; Marylène Plasse; Vincent Karam; Francis Lévi; Sylvie Giacchetti; Daniel Azoulay; Henri Bismuth; Denis Castaing; René Adam
Journal:  J Clin Oncol       Date:  2006-11-01       Impact factor: 44.544

7.  Sinusoidal injury increases morbidity after major hepatectomy in patients with colorectal liver metastases receiving preoperative chemotherapy.

Authors:  Hiroshi Nakano; Elie Oussoultzoglou; Edoardo Rosso; Selenia Casnedi; Marie-Pierre Chenard-Neu; Patrick Dufour; Philippe Bachellier; Daniel Jaeck
Journal:  Ann Surg       Date:  2008-01       Impact factor: 12.969

8.  Actual 10-year survival after resection of colorectal liver metastases defines cure.

Authors:  James S Tomlinson; William R Jarnagin; Ronald P DeMatteo; Yuman Fong; Peter Kornprat; Mithat Gonen; Nancy Kemeny; Murray F Brennan; Leslie H Blumgart; Michael D'Angelica
Journal:  J Clin Oncol       Date:  2007-10-10       Impact factor: 44.544

9.  Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.

Authors:  Herbert Hurwitz; Louis Fehrenbacher; William Novotny; Thomas Cartwright; John Hainsworth; William Heim; Jordan Berlin; Ari Baron; Susan Griffing; Eric Holmgren; Napoleone Ferrara; Gwen Fyfe; Beth Rogers; Robert Ross; Fairooz Kabbinavar
Journal:  N Engl J Med       Date:  2004-06-03       Impact factor: 91.245

10.  Systemic chemotherapy and two-stage hepatectomy for extensive bilateral colorectal liver metastases: perioperative safety and survival.

Authors:  Yun Shin Chun; Jean-Nicolas Vauthey; Dario Ribero; Matteo Donadon; John T Mullen; Cathy Eng; David C Madoff; David Z Chang; Linus Ho; Scott Kopetz; Steven H Wei; Steven A Curley; Eddie K Abdalla
Journal:  J Gastrointest Surg       Date:  2007-09-11       Impact factor: 3.452

View more
  9 in total

Review 1.  "Vanishing liver metastases"-A real challenge for liver surgeons.

Authors:  Alex Zendel; Eylon Lahat; Yael Dreznik; Barak Bar Zakai; Rony Eshkenazy; Arie Ariche
Journal:  Hepatobiliary Surg Nutr       Date:  2014-10       Impact factor: 7.293

Review 2.  Beyond Histologic Staging: Emerging Imaging Strategies in Colorectal Cancer with Special Focus on Magnetic Resonance Imaging.

Authors:  Tyler J Fraum; Joseph W Owen; Kathryn J Fowler
Journal:  Clin Colon Rectal Surg       Date:  2016-09

3.  Integrating Chemotherapy into the Management of Oligometastatic Colorectal Cancer: Evidence-Based Approach Using Clinical Trial Findings.

Authors:  Thomas J Semrad; Ana Rodriguez Fahrni; I-Yeh Gong; Vijay P Khatri
Journal:  Ann Surg Oncol       Date:  2015-06-23       Impact factor: 5.344

4.  Shifting trends in liver-directed management of patients with colorectal liver metastasis: a population-based analysis.

Authors:  Skye C Mayo; Jennifer E Heckman; Andrew D Shore; Hari Nathan; Alexander A Parikh; John F P Bridges; Robert A Anders; Daniel A Anaya; Natasha S Becker; Timothy M Pawlik
Journal:  Surgery       Date:  2011-08       Impact factor: 3.982

5.  Oridonin induces apoptosis and senescence in colorectal cancer cells by increasing histone hyperacetylation and regulation of p16, p21, p27 and c-myc.

Authors:  Feng-Hou Gao; Xiao-Hui Hu; Wei Li; Hua Liu; Yan-Jie Zhang; Zhu-Ying Guo; Mang-Hua Xu; Shi-Ting Wang; Bin Jiang; Feng Liu; Ying-Zheng Zhao; Yong Fang; Fang-Yuan Chen; Ying-Li Wu
Journal:  BMC Cancer       Date:  2010-11-06       Impact factor: 4.430

6.  Management of potentially resectable colorectal cancer liver metastases.

Authors:  Fausto Meriggi; Paola Bertocchi; Alberto Zaniboni
Journal:  World J Gastrointest Surg       Date:  2013-05-27

7.  Effects of somatic alterations at pathway level are more mechanism-explanatory and clinically applicable to quantity of liver metastases of colorectal cancer.

Authors:  Zhong-Guo Zhang; Fei Ma; Shuang Zhao; Xiaoyu Yang; Fang Liu; Chenghai Xue; Liren Liu; Jin Gu; Haozhe Piao
Journal:  Cancer Med       Date:  2019-06-20       Impact factor: 4.452

8.  Immunotherapy for metastatic liver disease from colorectal carcinoma: case series from the Middle East.

Authors:  Rasha T Kakati; Walid Faraj; Taha Qaraqe; Frederic El Chaer; Hero Hussain; Ali Shamseddine; Mohamad Jawad Khalife
Journal:  J Surg Case Rep       Date:  2022-08-31

9.  Hepatectomy for Breast Cancer Metastasis and Sarcoma are more likely to have Adverse Outcomes than Hepatectomy for Primary Hepatocellular Cancer or for Colorectal Metastasis.

Authors:  Hassan Aziz; Kamil Hanna; Muhammad Wasif Saif; Muhammad Ameen Rauf; Yuri Genyk; Mohd Raashid Sheikh
Journal:  Cancer Med J       Date:  2020-07-23
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.